Advertisement

Topics

HeartSciences Company Profile

00:50 EDT 20th August 2018 | BioPortfolio

HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wavECG™) is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.

In addition to proprietary informatics, the MyoVista wavECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wavECG Device is not currently FDA approved for commercial sale or distribution in the United States.

HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.

Corporate Contact
HeartSciences

Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com

Investor Contact
Zimmons International Communications, Inc.

Jennifer K. Zimmons, +1-917-214-3514
jzimmons@zimmonsic.com


News Articles [9 Associated News Articles listed on BioPortfolio]

Study shows positive results for HeartSciences' electrocardiogram system

A 188-patient study in the Journal of the American College of Cardiology showed that use of HeartSciences' MyoVista electroca -More- 

HeartSciences Showcases MyoVista® Wavelet ECG at the 2018 International Congress on Electrocardiology (ICE)

SOUTHLAKE, Texas, June 25, 2018 -- (BioPortfolio) — HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 Internat...

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 China International Medicinal Equipment Fair (CMEF)

Hall 5.1 USA-CEO Center (S26-32/R19-25-5) HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 20...

HeartSciences Announces Poster Presentation at the 2018 American College of Cardiology Scientific Sessions

HeartSciences also participates in the ACC Future Hub at Booth#3517, Space FH7 SOUTHLAKE, Texas, March 8, 2018 --(BUSINESSWIRE)—HeartSciences, an innovative medical device company, announced...

HeartSciences Showcases MyoVista® Wavelet ECG at the 2018 International Congress on Electrocardiology (ICE)

HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology...

HeartSciences Announces Professor Peter Macfarlane Joins Clinical Advisory Board

Southlake, Texas – May 2, 2018 – HeartSciences, a U.S.-based medical device company that is leading innovation in the field of electrocardiology through the application of continuous ...

HeartSciences Named “Start-Up to Watch”

HeartSciences is delighted to have been highlighted as “Start-Up to Watch” in the June 8, 2018 issue of the MedTech Strategist. The article titled

HeartSciences Announces Publication of Clinical Study Results in the Journal of the American College of Cardiology (JACC)

Study demonstrates promising new capabilities for MyoVista® ECG device in detecting Abnormal Cardiac Function SOUTHLAKE, Texas, April 10, 2018 - (BioPortfolio) HeartSciences, a medical...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

The MyoVista Angiography Angioplasty Percutaneous Coronary Intervention Trial

Purpose of this clinical investigation: clinical evaluation/accuracy of HeartSciences MyoVista High-Sensitivity (hsECG) 12 lead Electrocardiogram device, for patients presenting with cardi...

Companies [1 Associated Companies listed on BioPortfolio]

HeartSciences

HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal pr...

More Information about "HeartSciences" on BioPortfolio

We have published hundreds of HeartSciences news stories on BioPortfolio along with dozens of HeartSciences Clinical Trials and PubMed Articles about HeartSciences for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HeartSciences Companies in our database. You can also find out about relevant HeartSciences Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record